Facebook Twitter Instagram
Donate

Urgent Product Withdrawal – OXBRYTA ® (voxelotor)

Pfizer announces the withdrawal of OXBRYTA ® (voxelotor) for the treatment of sickle cell in all markets.

CLICK HERE TO LEARN MORE >>

Share this post

CONTACT US
  • Maryland Sickle Cell Disease Association
    8775 Centre Park Drive Suite 701
    Columbia, Maryland 21045
  • 410.465.4822
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Facebook Twitter Instagram
Scroll to Top